Breakthrough Against Pancreatic Cancer
A major breakthrough in the treatment of pancreatic cancer came when the U.S. Food and Drug Administration (FDA) approved daraxonrasib, an oral medication developed by Revolution Medicines. The approval followed the presentation of results from the phase 3 RASolute 302 clinical trial on May 31, 2026, at the annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago. The study included 500 patients with metastatic pancreatic cancer who had already received one prior line of systemic treatment and evaluated the drug's effectiveness and safety compared with chemotherapy selected by the investigators. The results prompted an unusual reaction at this type of scientific gathering. The oncologists in attendance rose to applaud the findings, giving a standing ovation that lasted approximately 42 seconds. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network, stated, “We had never seen a benefit like this.”
Median overall survival reached 13.2 months with daraxonrasib, compared with 6.7 months in the chemotherapy control group, representing a 60% relative reduction in the risk of death during the trial's follow-up period. Progression-free survival, meaning the length of time during which the disease did not worsen, was 7.2 months compared with 3.6 months. In addition, 30% of patients treated with daraxonrasib experienced an objective reduction in tumor size, compared with 11% of those who received chemotherapy. Patient-reported data also showed favorable results in certain measures of well-being and symptom control. These figures represent the outcomes of the groups studied and cannot predict how any individual patient will respond. Brian Wolpin, a researcher at the Dana-Farber Cancer Institute and the trial's principal investigator, recalled his surprise upon seeing the results: “I had never seen anything like this before in the pancreatic cancer trials we have conducted.”
The pancreas is a gland located deep in the abdomen that performs essential functions in digestion and blood glucose regulation. When a tumor develops in this organ, it is often detected late because the initial symptoms are nonspecific. This delay in diagnosis largely explains the disease's high mortality rate. According to the 2026 National Pancreatic Cancer Audit report, conducted in England and Wales, approximately 77% of patients with pancreatic cancer die within the first year after diagnosis. In the United States alone, pancreatic cancer is estimated to cause 52,740 deaths in 2026, according to the National Cancer Institute. Among patients whose cancer has already spread to distant organs, the five-year relative survival rate is approximately 3%.
For years, chemotherapy has been the primary treatment for advanced cases, capable of slowing disease progression but offering limited benefits. Numerous attempts to develop more effective drugs have failed. Although other options exist, including targeted therapies for certain groups of patients, treatment choices remain limited once the disease has spread to other organs. Finding drugs that can extend survival without significantly diminishing quality of life remains a priority for researchers.
To understand how daraxonrasib works, it is necessary to examine the role of RAS proteins, which help regulate cell growth and division. When these proteins remain abnormally activated, they can promote uncontrolled tumor growth. Alterations in the KRAS gene are particularly common in pancreatic adenocarcinoma and, for decades, represented one of the most difficult targets for researchers. Daraxonrasib is an oral RAS(ON) inhibitor that targets the active form of these proteins and interferes with the signals that drive cancer cell proliferation. Its ability to act against different RAS variants is one of the drug's most important characteristics.
The magnitude of the results led the treatment to receive priority regulatory review. On August 26, 2026, less than three months after the ASCO presentation, the U.S. Food and Drug Administration (FDA) approved daraxonrasib under the brand name Rasonque. It became the first RAS-targeted drug authorized for the treatment of pancreatic cancer. The approval was based primarily on the results of RASolute 302, which demonstrated statistically significant improvements in both overall survival and control of disease progression.
The authorization covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment or who are not candidates for combination systemic therapies. The medication is taken orally, with a recommended dose of 300 milligrams once daily, and is already commercially available in the United States. However, its price presents a significant challenge to treatment access. Revolution Medicines established a wholesale price of $39,800 for a 30-day supply, although the final cost to each patient depends on their health insurance coverage and available assistance programs. In other regions, such as Europe and Latin America, availability depends on regulatory approvals and each country's access mechanisms.
Specialists caution that important challenges remain. Daraxonrasib does not work for every patient, its benefits are not permanent, and it can cause side effects such as diarrhea, fatigue, nausea, inflammation of the oral mucosa, and skin rashes. The drug's official prescribing information also warns of potentially serious complications, including gastrointestinal perforation and interstitial lung disease or pneumonitis. For these reasons, treatment requires medical supervision and careful monitoring of side effects. Although the trial results represent considerable progress, the medication is not a cure, and its longer-term benefits and risks still need to be evaluated.
Despite these uncertainties, the breakthrough could have implications beyond pancreatic cancer. Numerous therapies targeting KRAS and other proteins in the RAS family are currently in various stages of development for cancers of the lung, colon, and other organs. Studies are also underway to evaluate daraxonrasib as an initial treatment for metastatic pancreatic cancer, in combination with chemotherapy, and in patients whose disease may be treated surgically. These investigations will help determine whether the observed benefits can be extended to other stages of the disease and a larger number of patients. The approval therefore represents tangible progress in an area of research that faced major scientific obstacles for decades and is now beginning to offer new treatment alternatives. Elizabeth Jaffee, a researcher at Johns Hopkins University, summed up the outlook for this new chapter in a simple phrase: “It's the beginning, not the end.”
Viviana Cetola, Reporter
Life News Today
Comments